Aligos Therapeutics’ (ALGS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report report published on Thursday,Benzinga reports. They currently have a $75.00 target price on the stock.

Aligos Therapeutics Stock Up 2.7 %

Shares of NASDAQ:ALGS opened at $10.19 on Thursday. The company has a 50 day moving average of $9.81 and a 200-day moving average of $12.57. Aligos Therapeutics has a twelve month low of $6.76 and a twelve month high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative return on equity of 105.36% and a negative net margin of 1,283.19%. During the same period in the prior year, the company posted ($10.25) earnings per share. On average, analysts expect that Aligos Therapeutics will post -8.2 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. Armistice Capital LLC lifted its stake in Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Opaleye Management Inc. increased its stake in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Aligos Therapeutics by 26.1% during the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after buying an additional 171,490 shares during the period. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).